Ifedayo Adetifa/Wellcome Open Res


3 results

TRUE-1: Trial of Repurposed Unithiol for snakebite Envenoming phase 1 (safety, tolerability, pharmacokinetics and pharmacodynamics in healthy Kenyan adults).Abouyannis M, FitzGerald R, Ngama M, Mwangudzah H, Nyambura YK, Ngome S, Riako D, Babu L, Lewa F, Else L, Dily Penchala S, Orindi B, Mumba N, Kalama B, Ndungu FM, Adetifa I, Khoo S, Lalloo DG, Casewell NR, Hamaluba M
Wellcome Open Res, (2022). 7:90

Revealing the extent of the first wave of the COVID-19 pandemic in Kenya based on serological and PCR-test data.Ojal J, Brand SPC, Were V, Okiro EA, Kombe IK, Mburu C, Aziza R, Ogero M, Agweyu A, Warimwe GM, Uyoga S, Adetifa IMO, Scott JAG, Otieno E, Ochola-Oyier LI, Agoti CN, Kasera K, Amoth P, Mwangangi M, Aman R, Ng'ang'a W, Tsofa B, Bejon P, Barasa E, Keeling MJ, Nokes DJ
Wellcome Open Res, (2021). 6:127

Crude childhood vaccination coverage in West Africa: Trends and predictors of completeness.Kazungu JS, Adetifa IMO
Wellcome Open Res, (2017). 2:12